Institutional investors have not been as broadly optimistic as they are today since the announcement of a COVID vaccine. It suggests they are becoming immune to policy uncertainty or at least believe such uncertainties have peaked.
Institutional investors have not been as broadly optimistic as they are today since the announcement of a COVID vaccine. It suggests they are becoming immune to policy uncertainty or at least believe such uncertainties have peaked.